Symbols / ARDS
ARDS Chart
About
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.91K |
| Enterprise Value | 4.81M | Income | -1.14M | Sales | 22.36M |
| Book/sh | -0.27 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 37 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | 0.00 | P/B | -0.00 | P/C | — |
| EV/EBITDA | -13.87 | EV/Sales | 0.21 | Quick Ratio | 0.03 |
| Current Ratio | 0.23 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.02 | EPS next Y | -0.09 | EPS Growth | — |
| Revenue Growth | 4.50% | Earnings | 2023-11-03 16:00 | ROA | -4.40% |
| ROE | — | ROIC | — | Gross Margin | 23.28% |
| Oper. Margin | -208.39% | Profit Margin | -5.11% | Shs Outstand | 44.57M |
| Shs Float | 38.42M | Short Float | 6.80% | Short Ratio | 0.22 |
| Short Interest | — | 52W High | 0.05 | 52W Low | 0.00 |
| Beta | 3463.64 | Avg Volume | 12.88K | Volume | 10.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-6.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-11-06 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-10-20 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-01-26 | main | HC Wainwright & Co. | — → Buy | $10 |
| 2022-08-16 | down | Maxim Group | Buy → Hold | — |
| 2021-07-20 | main | HC Wainwright & Co. | — → Buy | $19 |
| 2020-05-15 | reit | HC Wainwright & Co. | — → Buy | $11 |
| 2020-02-19 | init | Roth Capital | — → Buy | $18 |
| 2019-12-30 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2018-09-10 | init | Northcoast Research | — → Outperform | $40 |
| 2018-09-10 | init | Laidlaw & Co. | — → Buy | $23 |
| 2018-09-10 | init | Cantor Fitzgerald | — → Overweight | $25 |
- Edesa drug cuts death risk to 24% in Phase 3 ARDS trial - Stock Titan ue, 24 Feb 2026 14
- InflaRx stock halves after it drops lead drug - pharmaphorum Wed, 28 May 2025 07
- Edesa Biotech readies vitiligo trial after ARDS drug's Phase 3 success - Stock Titan Fri, 13 Feb 2026 08
- Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock - PR Newswire ue, 27 Sep 2022 07
- Arcadis stock rises following deal to buy WSP Infrastructure Engineering - Investing.com hu, 20 Mar 2025 07
- Lactate-to-Albumin Ratio Predicts Development of ARDS, Mortality Risk From Flu - Pharmacy Times hu, 19 Dec 2024 08
- Stock Up for the Spring: Earl Little Jr. - 247Sports Fri, 07 Mar 2025 08
- News Story #15667 - respiratory-therapy.com hu, 16 Nov 2023 03
- COVID-19 CLINICAL TRIAL - East Carolina University Wed, 10 Jun 2020 07
- Aridis Provides Corporate Update - Yahoo Finance Fri, 20 Dec 2024 08
- Survival high for patients undergoing lung transplant for COVID-19-associated ARDS - Healio Mon, 07 Feb 2022 08
- Faron Pharma flummoxed as Traumakine fails in ARDS - Fierce Biotech ue, 08 May 2018 07
- Novel treatment for life-threatening lung condition wins NSF support - Purdue University Wed, 17 Mar 2021 07
- Yale fibrosis drug may offer new treatment path for COVID-19 lung distress - YaleNews Fri, 03 Apr 2020 07
- From Crypto Art to Trading Cards, Investment Manias Abound (Published 2021) - The New York Times Fri, 23 Jun 2023 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 714286 | 50000 | — | Purchase at price 0.07 per share. | TRUONG VU | Chief Executive Officer | — | 2024-06-24 00:00:00 | D |
| 1 | 714286 | 50000 | — | Purchase at price 0.07 per share. | PATZER ERIC | Director | — | 2024-06-24 00:00:00 | D |
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 |
| NormalizedEBITDA | -29.51M | -43.00M |
| TotalUnusualItems | 0.00 | 722.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 722.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -30.37M | -42.19M |
| ReconciledDepreciation | 487.00K | 435.00K |
| EBITDA | -29.51M | -42.28M |
| EBIT | -29.99M | -42.71M |
| NetInterestIncome | -121.00K | -245.00K |
| NormalizedIncome | -30.37M | -42.91M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -30.37M | -42.19M |
| TotalExpenses | 29.99M | 42.71M |
| TotalOperatingIncomeAsReported | -29.99M | -42.71M |
| DilutedAverageShares | 18.78M | 12.29M |
| BasicAverageShares | 18.78M | 12.29M |
| DilutedEPS | -1.62 | -3.85 |
| BasicEPS | -1.62 | -3.85 |
| DilutedNIAvailtoComStockholders | -30.37M | -46.32M |
| NetIncomeCommonStockholders | -30.37M | -46.32M |
| OtherunderPreferredStockDividend | 0.00 | 4.13M |
| NetIncome | -30.37M | -42.19M |
| NetIncomeIncludingNoncontrollingInterests | -30.37M | -42.19M |
| NetIncomeContinuousOperations | -30.37M | -42.19M |
| PretaxIncome | -30.37M | -42.19M |
| OtherIncomeExpense | -257.00K | 763.00K |
| OtherNonOperatingIncomeExpenses | -257.00K | 41.00K |
| SpecialIncomeCharges | 0.00 | 722.00K |
| OtherSpecialCharges | -722.00K | |
| EarningsFromEquityInterest | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -121.00K | -245.00K |
| TotalOtherFinanceCost | 121.00K | 245.00K |
| OperatingIncome | -29.99M | -42.71M |
| OperatingExpense | 29.99M | 42.71M |
| OtherOperatingExpenses | -3.09M | -1.53M |
| ResearchAndDevelopment | 25.92M | 36.94M |
| SellingGeneralAndAdministration | 7.16M | 7.31M |
| GeneralAndAdministrativeExpense | 7.16M | 7.31M |
| OtherGandA | 7.16M | 7.31M |
| TotalRevenue | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| OrdinarySharesNumber | 27.03M | 17.70M |
| ShareIssued | 27.03M | 17.70M |
| TotalDebt | 6.13M | 5.98M |
| TangibleBookValue | -24.25M | -13.13M |
| InvestedCapital | -19.93M | -7.13M |
| WorkingCapital | -25.27M | -8.96M |
| NetTangibleAssets | -24.25M | -13.13M |
| CapitalLeaseObligations | 1.83M | 0.00 |
| CommonStockEquity | -24.23M | -13.11M |
| TotalCapitalization | -24.23M | -7.83M |
| TotalEquityGrossMinorityInterest | -24.23M | -13.11M |
| StockholdersEquity | -24.23M | -13.11M |
| GainsLossesNotAffectingRetainedEarnings | 5.05M | 0.00 |
| RetainedEarnings | -195.67M | -165.29M |
| AdditionalPaidInCapital | 166.38M | 152.18M |
| CapitalStock | 3.00K | 2.00K |
| CommonStock | 3.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 38.93M | 39.91M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.03M | 6.56M |
| OtherNonCurrentLiabilities | 363.00K | |
| NonCurrentDeferredLiabilities | 737.00K | 913.00K |
| NonCurrentDeferredRevenue | 737.00K | 913.00K |
| LongTermDebtAndCapitalLeaseObligation | 1.29M | 5.28M |
| LongTermCapitalLeaseObligation | 1.29M | 0.00 |
| LongTermDebt | 5.28M | |
| CurrentLiabilities | 36.90M | 33.35M |
| OtherCurrentLiabilities | 15.00K | 110.00K |
| CurrentDeferredLiabilities | 20.17M | 20.84M |
| CurrentDeferredRevenue | 20.17M | 20.84M |
| CurrentDebtAndCapitalLeaseObligation | 4.84M | 696.00K |
| CurrentCapitalLeaseObligation | 538.00K | 0.00 |
| CurrentDebt | 4.30M | 696.00K |
| CurrentNotesPayable | 4.30M | 696.00K |
| PayablesAndAccruedExpenses | 11.87M | 11.70M |
| CurrentAccruedExpenses | 9.56M | 6.46M |
| Payables | 2.31M | 5.24M |
| AccountsPayable | 2.31M | 5.24M |
| TotalAssets | 14.70M | 26.80M |
| TotalNonCurrentAssets | 3.07M | 2.41M |
| OtherNonCurrentAssets | 827.00K | 931.00K |
| NonCurrentDeferredAssets | 78.00K | 96.00K |
| GoodwillAndOtherIntangibleAssets | 17.00K | 22.00K |
| OtherIntangibleAssets | 17.00K | 22.00K |
| NetPPE | 2.15M | 1.36M |
| AccumulatedDepreciation | -2.04M | -1.58M |
| GrossPPE | 4.19M | 2.94M |
| Leases | 527.00K | 527.00K |
| ConstructionInProgress | 0.00 | |
| OtherProperties | 3.66M | 2.39M |
| MachineryFurnitureEquipment | 0.00 | 25.00K |
| Properties | 0.00 | 0.00 |
| CurrentAssets | 11.63M | 24.39M |
| CurrentDeferredAssets | 1.99M | 1.97M |
| RestrictedCash | 183.00K | 1.39M |
| PrepaidAssets | 3.34M | 2.70M |
| Receivables | 1.24M | 237.00K |
| OtherReceivables | 240.00K | 237.00K |
| AccountsReceivable | 1.00M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 4.88M | 18.10M |
| CashAndCashEquivalents | 4.88M | 18.10M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | -29.21M | -23.47M |
| RepaymentOfDebt | -1.80M | 0.00 |
| IssuanceOfDebt | 5.00M | 5.00M |
| IssuanceOfCapitalStock | 12.61M | 29.71M |
| CapitalExpenditure | -82.00K | -530.00K |
| IncomeTaxPaidSupplementalData | 19.00K | 2.00K |
| EndCashPosition | 5.56M | 19.99M |
| BeginningCashPosition | 19.99M | 8.73M |
| ChangesInCash | -14.43M | 11.25M |
| FinancingCashFlow | 14.78M | 34.72M |
| CashFlowFromContinuingFinancingActivities | 14.78M | 34.72M |
| NetOtherFinancingCharges | -1.03M | |
| ProceedsFromStockOptionExercised | 3.00K | 5.00K |
| NetCommonStockIssuance | 12.61M | 29.71M |
| CommonStockIssuance | 12.61M | 29.71M |
| NetIssuancePaymentsOfDebt | 3.20M | 5.00M |
| NetLongTermDebtIssuance | 3.20M | 5.00M |
| LongTermDebtPayments | -1.80M | 0.00 |
| LongTermDebtIssuance | 5.00M | 5.00M |
| InvestingCashFlow | -82.00K | -530.00K |
| CashFlowFromContinuingInvestingActivities | -82.00K | -530.00K |
| NetPPEPurchaseAndSale | -82.00K | -530.00K |
| PurchaseOfPPE | -82.00K | -530.00K |
| OperatingCashFlow | -29.13M | -22.94M |
| CashFlowFromContinuingOperatingActivities | -29.13M | -22.94M |
| ChangeInWorkingCapital | -1.30M | 10.52M |
| ChangeInOtherWorkingCapital | -841.00K | 2.15M |
| ChangeInOtherCurrentLiabilities | -30.00K | 0.00 |
| ChangeInOtherCurrentAssets | 104.00K | 56.00K |
| ChangeInPayablesAndAccruedExpense | 259.00K | 8.00M |
| ChangeInAccruedExpense | 3.19M | 5.35M |
| ChangeInPayable | -2.93M | 2.65M |
| ChangeInAccountPayable | -2.93M | 2.65M |
| ChangeInPrepaidAssets | 212.00K | 178.00K |
| ChangeInReceivables | -1.00M | 131.00K |
| ChangesInAccountReceivables | -1.00M | 0.00 |
| OtherNonCashItems | 350.00K | 6.78M |
| StockBasedCompensation | 1.48M | 2.25M |
| AssetImpairmentCharge | 227.00K | 0.00 |
| DepreciationAmortizationDepletion | 487.00K | 435.00K |
| DepreciationAndAmortization | 487.00K | 435.00K |
| OperatingGainsLosses | -722.00K | |
| EarningsLossesFromEquityInvestments | 0.00 | |
| NetIncomeFromContinuingOperations | -30.37M | -42.19M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ARDS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|